EUROLAB
ich-s9-impurities-in-oncology-products
Impurity Profiling EMA Guideline on Genotoxic Impurities in PharmaceuticalsEMA Reflection Paper on Low Level ImpuritiesFDA Guidance: Microbial Impurities and Endotoxin LevelsFDA Guidance: Threshold of Toxicological Concern (TTC) for ImpuritiesFDA ICH M3(R2): Impurities in Safety StudiesFDA Q&A on Impurities in Generic Drug ApplicationsFDA Q&A: Managing Impurities in Complex APIsICH E14: QT Interval Evaluation and Impurity ImpactICH M7: Mutagenic Impurity Risk AssessmentICH Q10: Pharmaceutical Quality System for Impurity ManagementICH Q11: Impurity Control Strategy in Drug Substance DevelopmentICH Q12: Lifecycle Management of Impurity Control StrategyICH Q1E: Evaluation of Stability Data Related to Impurity FormationICH Q2(R1): Validation of Analytical Methods for Impurity TestingICH Q3A: Organic Impurity Profiling in Drug SubstancesICH Q3B: Impurity Testing in Finished Drug ProductsICH Q3C: Residual Solvent ProfilingICH Q3D: Elemental Impurity Risk AssessmentICH Q3F: Impurity Guidelines for Biotechnology ProductsICH Q4B: Harmonization of Analytical Procedures for Impurity TestingICH Q5C: Impurity Monitoring in Biotechnological ProductsICH Q6A: Specifications and Acceptance Criteria for ImpuritiesICH S3A: Impurities Arising from Degradation ProductsICH S6: Biotech Product Impurity ProfilingICH S7A: Safety Pharmacology Impurity EvaluationISO 10993-18: Chemical Characterization and Impurity AnalysisISO 17025: Accreditation for Impurity Testing LaboratoriesJP General Rule 2.60: Limit Test for ImpuritiesPh. Eur. 2.2.28: Gas Chromatography for Impurity DetectionPh. Eur. 2.2.38: Thin-Layer Chromatography for ImpuritiesPh. Eur. 2.2.46: Chromatographic Separation for Impurity AnalysisPh. Eur. 2.4.14: Determination of Inorganic ImpuritiesPh. Eur. 2.4.20: Limit Test for Heavy Metals in ImpuritiesPh. Eur. 2.4.24: Related Substances by HPLC in APIsPh. Eur. 2.4.29: Limit Test for Sulfated Ash ImpuritiesPh. Eur. 2.5.13: Oxidizing Impurity TestsPh. Eur. 2.9.40: Uniformity of Dosage Units and Related ImpuritiesPh. Eur. 5.10: Control of Impurities in Substances for Pharmaceutical UsePh. Eur. 5.4: Impurities in Radiopharmaceutical PreparationsUSP <1010>: Analytical Data Integrity in Impurity ReportingUSP <1031>: The Biocompatibility of Materials and ImpuritiesUSP <1051>: Cleaning Validation Limits and Residual ImpuritiesUSP <1058>: Analytical Instrument Qualification for Impurity StudiesUSP <1078>: Good Manufacturing Practices for Impurity ReductionUSP <1085>: Evaluation of Impurity Method PerformanceUSP <1086>: Impurities in Drug SubstancesUSP <1088>: Forced Degradation Studies for Impurity CharacterizationUSP <1091>: Impurity Isolation and Characterization TechniquesUSP <1099>: Acceptable Analytical Performance CriteriaUSP <1121>: Bulk Pharmaceutical Chemicals and Impurity HandlingUSP <1151>: Pharmaceutical Dosage Forms and Impurity ConsiderationUSP <1191>: Stability Testing of Compounded PreparationsUSP <1222>: Terminal Sterilization Impact on ImpuritiesUSP <1224>: Transfer of Impurity Test ProceduresUSP <1225>: Validation of Compendial Procedures for ImpuritiesUSP <1226>: Verification of Compendial Procedures for Impurity DetectionUSP <1231>: Water for Pharmaceutical Purposes and Impurity EffectsUSP <1232>: Water Activity and Impurity StabilityUSP <1241>: Capsules and Shell Impurity InteractionUSP <1251>: Weighing on Analytical Balances for Micro-ImpuritiesUSP <161>: Transdermal Delivery Systems and Impurity ControlUSP <197>: Spectrophotometric Identification of ImpuritiesUSP <233>: Elemental Impurities Profiling Using ICP-MSUSP <41>: Balances Used for Impurity Weight DeterminationUSP <466>: Identification and Quantification of DegradantsUSP <467>: Residual Solvent Testing in APIs and ExcipientsUSP <476>: Impurity Profiling for New Drug ApplicationsUSP <621>: Chromatography Conditions for Impurity IdentificationUSP <730>: Plasma Spectrochemistry for Impurity ProfilingUSP <791>: pH Determination Impact on Impurity SolubilityUSP <797>: Sterile Compounding and Impurity ControlUSP <800>: Hazardous Drug Handling Based on Impurity RiskUSP <851>: Spectrophotometry and Light Scattering for ImpuritiesUSP <853>: Atomic Absorption Spectroscopy for Trace ImpuritiesUSP <857>: UV-Vis Spectroscopy for Impurity QuantificationUSP <85>: Bacterial Endotoxin Limits Related to Impurity SafetyUSP <891>: Nuclear Magnetic Resonance (NMR) for Structural ElucidationUSP <905>: Content Uniformity Related to ImpuritiesUSP <905>: Uniformity of Dosage Units Affected by ImpuritiesUSP <941>: Characterization of Impurity Solubility and pKaWHO TRS 970 Annex 2: Impurity Control in Medicines

Comprehensive Guide to ICH S9: Impurities in Oncology Products Laboratory Testing Service

ICH S9 is a harmonized guideline developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). This guideline addresses the detection and control of impurities in oncology products, including pharmaceuticals, biotechnology-derived therapeutic substances, and vaccines. The standard aims to ensure the safety and efficacy of these products by establishing acceptable limits for residual solvents, impurities, and degradation products.

Legal and Regulatory Framework

The legal and regulatory framework surrounding ICH S9 is governed by national and international regulations, including:

  • European Pharmacopoeia (EP)
  • United States Pharmacopeia (USP)
  • International Conference on Harmonisation (ICH) guidelines
  • Good Manufacturing Practice (GMP)
  • Good Laboratory Practice (GLP)
  • These regulations establish the requirements for testing and controlling impurities in oncology products. Manufacturers must comply with these standards to ensure product safety and efficacy.

    International and National Standards

    Several international and national standards apply to ICH S9 testing, including:

  • ISO 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories
  • ASTM E2754-14 Standard Guide for the Quality System in the Testing Laboratory
  • EN ISO/IEC 17025:2005 General requirements for the competence of testing and calibration laboratories
  • TSE (Turkish Standards Institution) TS EN ISO 17025:2017
  • These standards ensure that testing laboratories like Eurolab meet the required competencies and follow established procedures.

    Standard Development Organizations

    The standard development process is overseen by organizations such as:

  • International Organization for Standardization (ISO)
  • American Society for Testing and Materials (ASTM)
  • European Committee for Standardization (CEN)
  • These organizations develop, maintain, and update standards to ensure they remain relevant and effective.

    Evolution of Standards

    Standards evolve over time to reflect new technologies, scientific advancements, and changing regulatory requirements. Manufacturers must stay informed about updates to ICH S9 guidelines to ensure compliance.

    Standard Numbers and Scope

    Some key standard numbers and their scope include:

  • ISO 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories
  • ASTM E2754-14 Standard Guide for the Quality System in the Testing Laboratory
  • EN ISO/IEC 17025:2005 General requirements for the competence of testing and calibration laboratories
  • These standards establish the framework for ICH S9 testing.

    Standard Compliance Requirements

    Different industries have varying compliance requirements. Manufacturers must ensure they meet the specific regulatory demands for their products, such as:

  • Pharmaceuticals: USP <233> Impurities in Pharmaceutical Articles
  • Biotechnology-derived therapeutic substances: EP 2.6.1 Sterility of Biological Preparations
  • Vaccines: WHO Requirements for Vaccine Quality
  • Standard-Related Information Table

    Standard Scope

    --- ---

    ISO 17025:2017 General requirements for the competence of testing and calibration laboratories

    ASTM E2754-14 Standard Guide for the Quality System in the Testing Laboratory

    EN ISO/IEC 17025:2005 General requirements for the competence of testing and calibration laboratories

    Standard Compliance Requirements Table

    Industry Regulatory Body Standard Numbers

    --- --- ---

    Pharmaceuticals USP, ICH <233> Impurities in Pharmaceutical Articles, S9

    Biotechnology-derived therapeutic substances EP, WHO 2.6.1 Sterility of Biological Preparations, QRs (Quality Requirements)

    Vaccines WHO Requirements for Vaccine Quality

    Standard-Related Information and Compliance Table

    The tables above summarize the standard-related information and compliance requirements.

    Why this Specific Test is Needed and Required

    ICH S9 testing is essential to ensure product safety and efficacy. Impurities in oncology products can have serious health implications, including:

  • Toxicity
  • Mutagenicity
  • Carcinogenicity
  • Immunotoxicity
  • These risks necessitate strict control of impurities.

    Business and Technical Reasons for Conducting ICH S9 Testing

    Manufacturers must perform ICH S9 testing to comply with regulations and ensure product safety. This testing is a critical component of their quality management system.

    Consequences of Not Performing this Test

    Failure to conduct ICH S9 testing can result in:

  • Product recalls
  • Regulatory non-compliance
  • Reputation damage
  • Financial losses
  • These consequences highlight the importance of performing this test.

    Industries and Sectors that Require this Testing

    Several industries require ICH S9 testing, including:

  • Pharmaceuticals
  • Biotechnology-derived therapeutic substances
  • Vaccines
  • Risk Factors and Safety Implications

    Impurities in oncology products can pose significant risks to human health. Manufacturers must control these impurities to ensure product safety.

    ICH S9 Testing Requirements Table

    Industry Regulatory Body Standard Numbers

    --- --- ---

    Pharmaceuticals USP, ICH <233> Impurities in Pharmaceutical Articles, S9

    Biotechnology-derived therapeutic substances EP, WHO 2.6.1 Sterility of Biological Preparations, QRs (Quality Requirements)

    Vaccines WHO Requirements for Vaccine Quality

    Standard Requirements and Needs Table

    The table above summarizes the standard requirements and needs.

    Standard-Related Information and Compliance Table

    This table provides a summary of the standard-related information and compliance requirements.

    Standard Requirements and Needs Figure

    Insert figure: ICH S9 Testing Requirements Flowchart

    The flowchart illustrates the testing requirements for oncology products.

    Conclusion

    ICH S9 is an essential guideline that ensures product safety and efficacy. Manufacturers must comply with these standards to avoid regulatory non-compliance, reputation damage, and financial losses. Eurolabs expertise in ICH S9 testing ensures manufacturers can meet these requirements.

    References

  • ICH Q3A(R2) Impurities: Guideline for Residual Solvents
  • ICH Q3B(R) Impurities: Guideline for Impurities: Residual Solvents, Moisture, and Other Inorganic Impurities
  • USP <233> Impurities in Pharmaceutical Articles
  • EP 2.6.1 Sterility of Biological Preparations
  • The references provide a comprehensive overview of the standard-related information and compliance requirements.

    Please note that this is just an excerpt from the comprehensive guide. If you would like me to continue with the rest of the document, please let me know.

    Need help or have a question?
    Contact us for prompt assistance and solutions.

    Latest News

    View all

    JOIN US
    Want to make a difference?

    Careers